Mazindol for Cocaine Abuse - 2 - Full Text View

Mazindol for Cocaine Abuse - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000277

Purpose

The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Mazindol	Phase II

ChemIDplus related topics:

8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Mazindol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Mazindol for Cocaine Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Drug use
Retention

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000277

Locations


United States, Connecticut
	VA Connecticut Healthcare System
	New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators


Principal Investigator:	Thomas R Kosten, M.D.	VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-09250-2, P50-09250-2
First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000277
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders

Dopamine

Mental Disorders

Mazindol

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Adrenergic Uptake Inhibitors

Therapeutic Uses

Physiological Effects of Drugs

Dopamine Agents

Central Nervous System Stimulants

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2008